Browsing by Author "Mestres i López, Jordi"

Sort by: Order: Results:

  • Gregori Puigjané, Elisabet (Universitat Pompeu Fabra, 2008-07-08)
    La representació de les molècules per mitjà de descriptors moleculars és la base de moltes de les eines computacionals pel disseny de fàrmacs. Aquests mètodes computacionals es basen en l'abstracció de l'estructura química ...
  • Bauer-Mehren, Anna; van Mulligen, Erik M.; Avillach, Paul; Carrascosa Baena, María Carmen, 1972-; García Serna, Ricard; Piñero González, Janet, 1977-; Singh, Barat; Lopes, Pedro; Oliveira, José Luis; Diallo, Gayo; Ahlberg Helgee, Ernst; Boyer, Scott; Mestres i López, Jordi; Sanz, Ferran; Kors, Jan A.; Furlong, Laura I., 1971- (Public Library of Science (PLoS), 2012)
    Drug safety issues pose serious health threats to the population and constitute a major cause of mortality worldwide. Due to the prominent implications to both public health and the pharmaceutical industry, it is of great ...
  • García Serna, Ricard (Universitat Pompeu Fabra, 2010-09-27)
    The work on this thesis has focused on the development of integrated databases and visualization tools for three related areas of biomedical sciences involved in the drug discovery process. An annotated chemical library ...
  • Sultana, Janet; Calabro, Marco; Garcia-Serna, Ricard; Ferrajolo, Carmen; Crisafulli, Concetta; Mestres i López, Jordi; Trifirò, Gianluca (Public Library of Science (PLoS), 2017)
    INTRODUCTION: Antipsychotic (AP) safety has been widely investigated. However, mechanisms underlying AP-associated pneumonia are not well-defined. AIM: The aim of this study was to investigate the known mechanisms of ...
  • Flachner, Beáta; Lorincz, Zsolt; Carotti, Angelo; Nicolotti, Orazio; Kuchipudi, Praveena; Kuchipudi, Praveena; Remez Vinogradov, Nikita, 1985-; Sanz, Ferran; Tóvári, József; Szabo, Miklós J; Bertók, Béla; Cseh, Sándor; Mestres i López, Jordi; Dormán, György (Public Library of Science (PLoS), 2012)
    A novel chemocentric approach to identifying cancer-relevant targets is introduced. Starting with a large chemical collection, the strategy uses the list of small molecule hits arising from a differential cytotoxicity ...
  • Jalencas i Giménez, Xavier, 1981- (Universitat Pompeu Fabra, 2013-09-17)
    In medicinal chemistry, two chemical fragments are considered bioisosteric if they bind to the same protein environment. Accordingly, looking at the same players from an opposite perspective, two protein environments can ...
  • Briansó, Ferran; Carrascosa Baena, María Carmen, 1972-; Oprea, Tudor I.; Mestres i López, Jordi (Bentham Science Publishers, 2011)
    The degree of applicability of chemogenomic approaches to protein families depends on the accuracy and completeness of pharmacological data and the corresponding level of pharmacological similarity observed among their ...
  • Remez Vinogradov, Nikita, 1985- (Universitat Pompeu Fabra, 2016-02-08)
    The explosion of reductionist approaches at the end of the XXth century allowed for fast and high-throughput data collection in pharmaceutical industry, but did not deliver the expected gain in drug discovery performance. ...
  • Coloma, Preciosa M.; Furlong, Laura I., 1971-; Bauer-Mehren, Anna; Sanz, Ferran; Mestres i López, Jordi; Sturkenboom, Miriam (Public Library of Science (PLoS), 2013)
    Background: Drug-related adverse events remain an important cause of morbidity and mortality and impose huge burden on healthcare costs. Routinely collected electronic healthcare data give a good snapshot of how drugs are ...
  • Antolín Hernández, Albert, 1984-; Mestres i López, Jordi (American Chemical Society (ACS), 2018)
    Recent network and system biology analyses suggest that most complex diseases are regulated by robust and highly interconnected pathways that could be better modulated by small molecules binding to multiple biological ...
  • Olivés Farrés, Joaquim, 1987- (Universitat Pompeu Fabra, 2017-01-30)
    L'habilitat de petites molècules per interaccionar amb múltiples proteines no és exclusiva dels fàrmacs, sino de la majoria de compostos, incloent els metabòlits endogens dels organismes, desde les plants fins els humans. ...
  • Lopes, Pedro; Nunes, Tiago; Campos, David; Furlong, Laura I., 1971-; Bauer-Mehren, Anna; Sanz, Ferran; Carrascosa Baena, María Carmen, 1972-; Mestres i López, Jordi; Kors, Jan A.; Singh, Barat; van Mulligen, Erik M.; van der Lei, Johan; Diallo, Gayo; Avillach, Paul; Ahlberg Helgee, Ernst; Boyer, Scott; Díaz, Carlos; Oliveira, José Luis (Public Library of Science (PLoS), 2013)
    Pharmacovigilance plays a key role in the healthcare domain through the assessment, monitoring and discovery of interactions amongst drugs and their effects in the human organism. However, technological advances in this ...
  • Rubio Pérez, Carlota, 1990-; Tamborero Noguera, David; Schroeder, Michael Philipp, 1986-; Antolín Hernández, Albert, 1984-; Déu Pons, Jordi; Pérez Llamas, Christian, 1976-; Mestres i López, Jordi; González-Pérez, Abel; López Bigas, Núria (Elsevier, 2015)
    Large efforts dedicated to detect somatic alterations across tumor genomes/exomes are expected to produce significant improvements in precision cancer medicine. However, high inter-tumor heterogeneity is a major obstacle ...
  • Rubio Pérez, Carlota; Tamborero Noguera, David; Schroeder, Michael Philipp, 1986-; Antolín Hernández, Albert, 1984-; Déu Pons, Jordi; Pérez Llamas, Christian, 1976-; Mestres i López, Jordi; González-Pérez, Abel; López Bigas, Núria (Universitat Pompeu Fabra, 2015-03)
    This database contains data on the interactions with therapeutic agents an driver genes contained in Cancer Drivers Database (2014.12). It characterizes the interacting therapeutic agents in terms of clinical phase and ...
  • Rubio Pérez, Carlota; Tamborero Noguera, David; Schroeder, Michael Philipp, 1986-; Antolín Hernández, Albert, 1984-; Déu Pons, Jordi; Pérez Llamas, Christian, 1976-; Mestres i López, Jordi; González-Pérez, Abel; López Bigas, Núria (Universitat Pompeu Fabra, 2015-03)
    This database contains information on the genes identified as drivers in Rubio-Perez and Tamborero et al. (2015). It contains information on driver identification at mutational, CNA and gene fusion level. Additional ancillary ...
  • Sanz, Ferran; Pastor Maeso, Manuel; Mestres i López, Jordi; Zamora Rico, Ismael (Nature Publishing Group, 2017)
    The sharing of legacy preclinical safety data among pharmaceutical companies and its integration with other information sources offers unprecedented opportunities to improve the early assessment of drug safety. Here, we ...
  • Carrascosa Baena, María Carmen, 1972- (Universitat Pompeu Fabra, 2018-03-20)
    El paradigma clàssic on un medicament interacciona amb un únic target biològic vinculat a una malaltia es posa en dubte. Actualment es reconeix que un medicament interacciona amb múltiples targets biològics i que aquests ...
  • Van Voorhis, Wesley C.; Mestres i López, Jordi; Spitzmüller, Andreas; Willis, Paul A. (Public Library of Science (PLoS) , 2016)
    A major cause of the paucity of new starting points for drug discovery is the lack of interaction between academia and industry. Much of the global resource in biology is present in universities, whereas the focus of ...
  • Carrascosa Baena, María Carmen, 1972-; Massaguer, Oriol L.; Mestres i López, Jordi (Wiley-VCH Verlag, 2012)
  • Szabó, Viktória, 1986- (Universitat Pompeu Fabra, 2019-03-13)
    The demographic shift toward an aging population is increasing the burden of public health. On average, a person of 70 years can combine the intake of up to seven medications. The administration of multiple drugs at the ...